Garadacimab

Definition

A humanized monoclonal antibody against the activated coagulation factor XIIa (FXIIa), with potential anti-inflammatory and anticoagulant activities. Upon administration, garadacimab targets and binds to FXIIa, blocking the activation of both the kallikrein-kinin system and the intrinsic pathway of coagulation. Blocking the activation of the kallikrein-kinin system may reduce inflammation as well as the production of bradykinin (BK). This may prevent BK-driven edema in hereditary angioedema (HAE). Blocking the activation of the intrinsic pathway of coagulation may lead to anti-coagulation. This may also prevent or improve pulmonary edema not associated with HAE and improve the associated decrease in blood oxygen levels.

Also known as CSL 312, CSL-312, CSL312, GARADACIMAB — per NCIT

Also identified as

• ATC B06AC07 per RXNORM
• NCIT NCIT:C166633 per NCIT
• UNII 32W6AJL0DY per RXNORM

Indications